From Capecitabine to Tucatinib: Data Reveal New Treatment Options for Patients
Significant study results could inform clinical practice strategies.
Source: pharmacytimes.com
📰 Genentech News
Page 53 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
From Axatilimab to Zanubrutinib: Treatment Updates Abound
Presentations detail clinical trial results and focus on drugs in the pipeline.
Source: pharmacytimes.com
ARVO Foundation announces 2024 recipient of Genentech Career Development Award for Underrepresented Minority Emerging Vision Scientists
Rockville, Md.—The Association for Research in Vision and Ophthalmology (ARVO) Foundation congratulates Diana C. Lozano, PhD, who was awarded the 2024 Genente
United States South San Francisco Dianac Lozano Association For Research Foundation For Eye Research Roche Group
Source: newswise.com
Apple becomes the first big tech company with a gender-equal board of directors
The retirement of Al Gore and James Bell and the appointment of Wanda Austin mean there will be an equal number of men and women in the group’s executive committee
Source: elpais.com
Biosimilars Provide New Treatment Opportunities For Wide Range of Conditions
Biosimilars are proven to be highly similar to the original products with no clinical meaningful differences.
United States Rezvoglar Kwikpen Coherus Biosciences Overview For Health Care Professionals Boehringer Ingelheim American Cancer Society
Source: pharmacytimes.com
Red Biotechnology Market Size, Share, Growth Trends and Forecast 2022-2030
The Red Biotechnology Market Size accounted for USD 360.3 Billion in 2022 and is estimated to achieve a market size of USD 656.1 Billion by 2032 growing at a CAGR of 6.3% from 2023 to 2032.
United States Cmos Cros Academic Research Institutes Market Research Publishers Biotechnology Companies Roche Group
Source: whatech.com
Dual-Acting CAR T-Cell Therapy May Address Unmet Need in the Treatment of Patients with B-Cell Malignancies
New CAR T development method infuses immune T cells from healthy people into patients to improve outcomes.
Source: pharmacytimes.com
Manufacturing Issues Block Astellas From a First-in-Class Cancer Drug Approval
Astellas Pharma’s zolbetuximab was on track to become the first gastric cancer drug that targets claudin 18.1, a protein found on cancerous stomach cells. Others with clinical-stage programs addressing this this target include AstraZeneca and Bristol Myers Squibb.
Moitreyee Chatterjee Kishore Daiichi Sankyo Astellas Pharma Jiangsu Hengrui Pharmaceuticals Ganymede Pharmaceuticals Merck Kga
Source: medcitynews.com
Former university president retracts 'groundbreaking' Alzheimer's paper
(THE COLLEGE FIX) – Former Stanford University President Marc Tessier-Lavigne, who resigned in July of last year after an investigation found flaws in his research, retracted a 2009 science paper formerly described as “groundbreaking.” The prestigious science journal Nature announced the retraction in a December 18 article signed by Tessier-Lavigne (pictured), the lead author, and…
Source: wnd.com
Former Stanford President Retracts "Ground-Breaking" Alzheimer's Paper
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Source: zerohedge.com